TARSUS PHARMACEUTICALS INC · Data as of 2026-09-08
Late 2026
A Phase 2 study of TP-04 (lotilaner ophthalmic gel) for the potential treatment of ocular rosacea (OR), a highly prevalent and underserved eye disease with no FDA-approved therapy, in December 2025, with topline data expected by year-end 2026.Source filing
H1 2027
The Phase 2 KORE trial evaluating TP-04, a lotilaner-based sterile ophthalmic gel formulation for the potential treatment of ocular rosacea, continues to progress, with topline data expected in the first half of 2027.Source filing
2027
In Europe, on-track for potential approval of a preservative-free formulation in 2027.Source filing
in 2028
Anticipated to initiate the Phase 3 COMFORT trial of IRX-101, an investigational ocular antiseptic, in the first half of 2027, with topline results expected in 2028.Source filing
H2 2029
Top-line Phase 3 NORTHSTAR data expected in the second half of 2029; Has Received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designationsSource filing